MX2021015877A - Receptores de celulas t que reconocen la mutacion r175h o y220c en p53. - Google Patents

Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.

Info

Publication number
MX2021015877A
MX2021015877A MX2021015877A MX2021015877A MX2021015877A MX 2021015877 A MX2021015877 A MX 2021015877A MX 2021015877 A MX2021015877 A MX 2021015877A MX 2021015877 A MX2021015877 A MX 2021015877A MX 2021015877 A MX2021015877 A MX 2021015877A
Authority
MX
Mexico
Prior art keywords
cell receptors
mutation
recognize
mammal
human
Prior art date
Application number
MX2021015877A
Other languages
English (en)
Spanish (es)
Inventor
Steven A Rosenberg
Drew C Deniger
Anna Pasetto
Parisa Malekzadeh
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2021015877A publication Critical patent/MX2021015877A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
MX2021015877A 2019-06-27 2020-06-26 Receptores de celulas t que reconocen la mutacion r175h o y220c en p53. MX2021015877A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867619P 2019-06-27 2019-06-27
PCT/US2020/039785 WO2020264269A1 (en) 2019-06-27 2020-06-26 T cell receptors recognizing r175h or y220c mutation in p53

Publications (1)

Publication Number Publication Date
MX2021015877A true MX2021015877A (es) 2022-04-18

Family

ID=71662353

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015877A MX2021015877A (es) 2019-06-27 2020-06-26 Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.

Country Status (11)

Country Link
US (1) US12479902B2 (https=)
EP (1) EP3990481A1 (https=)
JP (2) JP7635165B2 (https=)
KR (1) KR20220047969A (https=)
CN (1) CN114341171A (https=)
AU (1) AU2020308004B2 (https=)
BR (1) BR112021026408A2 (https=)
CA (1) CA3144070A1 (https=)
MX (1) MX2021015877A (https=)
TW (2) TWI908730B (https=)
WO (1) WO2020264269A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210189336A1 (en) * 2017-10-18 2021-06-24 Vivia Biotech, S.L. Bite-activated car-t cells
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
US20240209058A1 (en) * 2021-04-30 2024-06-27 Regents Of The University Of Minnesota Mesothelin-specific T cell Receptors and Methods of Using Same
AU2022271195A1 (en) * 2021-05-03 2023-11-02 Bluesphere Bio, Inc. T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1
WO2022236050A1 (en) * 2021-05-07 2022-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
EP4423143A4 (en) * 2021-10-29 2025-10-01 Yafei Hou T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
WO2024076692A1 (en) * 2022-10-05 2024-04-11 Icahn School Of Medicine At Mount Sinai Heterobifunctional compounds as p53 acetylators
WO2024163371A1 (en) * 2023-01-30 2024-08-08 Fred Hutchinson Cancer Center Binding proteins specific for mutant p53 and uses thereof
WO2024206274A2 (en) 2023-03-27 2024-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
WO2024220520A2 (en) * 2023-04-21 2024-10-24 Board Of Regents, The University Of Texas System T-cell receptors targeting her2 and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
IL290655B2 (en) 2014-05-29 2024-05-01 Us Health Anti-human papillomavirus 16 E7 T-cell chelates
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
CN107748893A (zh) * 2017-09-29 2018-03-02 阿里巴巴集团控股有限公司 提升车辆定损图像识别结果的方法、装置及服务器
CA3080274A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
EA202090757A1 (ru) 2017-09-29 2020-08-21 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
WO2022236050A1 (en) 2021-05-07 2022-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
WO2024206274A2 (en) 2023-03-27 2024-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53

Also Published As

Publication number Publication date
CA3144070A1 (en) 2020-12-30
BR112021026408A2 (pt) 2022-02-08
US12479902B2 (en) 2025-11-25
JP2022538148A (ja) 2022-08-31
TW202525841A (zh) 2025-07-01
WO2020264269A1 (en) 2020-12-30
US20220332785A1 (en) 2022-10-20
TW202108609A (zh) 2021-03-01
TWI908730B (zh) 2025-12-21
JP2025081413A (ja) 2025-05-27
EP3990481A1 (en) 2022-05-04
JP7635165B2 (ja) 2025-02-25
AU2020308004A1 (en) 2022-02-03
CN114341171A (zh) 2022-04-12
AU2020308004B2 (en) 2026-03-19
KR20220047969A (ko) 2022-04-19

Similar Documents

Publication Publication Date Title
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
MX2020003504A (es) Receptores de celulas t que reconocen p53 mutado.
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
MX2024004610A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
SA518391109B1 (ar) Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ
CY1123385T1 (el) Υψηλης συγγενειας pd-1 παραγοντες και μεθοδοι χρησης
MX2016015383A (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
BR112021022874A2 (pt) Proteínas de ligação epcam e métodos de uso
EA202092044A1 (ru) Химерные рецепторы антигена против cd33 и их применения
MX2017006865A (es) Receptores de células t de kras anti-mutado.
BR112022000641A2 (pt) Modificação genética de célula efetora imune e uso da mesma
MX2019009641A (es) Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida.
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
MX2021001158A (es) Vector hsv oncolitico.
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
JOP20210186A1 (ar) مستضدات البروستاتا المستحدثة واستخداماتها
CO2022012922A2 (es) Receptor de células t restringido por hla de la clase i contra ras con mutación g12d
MX2022009825A (es) Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
EA201791918A1 (ru) Модификация белков клеток-хозяев
WO2016077525A3 (en) Human anti-thyroglobulin t cell receptors
WO2024206274A3 (en) T cell receptors targeting y220c or r175h mutation in p53